This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option.
The U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly), a once-daily pill, on Monday. It's meant to be taken with the cancer drug everolimus.
The pairing is for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that has grown into nearby tissue or spread to other parts of the body.
ER-positive cancers feed on the hormone estrogen to grow. HER2-negative means the tumor doesn't make high levels of a growth protein called HER2.
Over time, though, many of these tumors develop a change in a gene called ESR1 that helps them slip past hormone drugs. Up to 40% of patients with this type of advanced breast cancer develop ESR1 mutations, Roche said in a news release.
The new approval covers only patients whose tumors carry that mutation and whose cancer came back or got worse despite earlier hormone therapy.
To find these patients, the FDA also authorized a blood test called FoundationOne Liquid CDx. It checks for bits of tumor DNA circulating in the bloodstream.
Giredestrant latches onto estrogen receptors on cancer cells, blocking estrogen and causing the receptors to break down. Everolimus shuts down a separate pathway that cancer cells use to grow.
The approval is based on a trial of 373 adults with ER+, HER2- breast cancer whose cancer had advanced after earlier treatment.
Source link







